Novavax and Serum Institute of India Announce Submission to Regulatory Agencies in India, Indonesia, Philippines for Emergency Use Authorization of Novavax’ Recombinant Nanoparticle COVID-19 Vaccine
– Novavax and Serum Institute of India file regulatory submissions to the Drugs Controller General of India and to regulatory agencies in Indonesia and Philippines for Novavax’ recombinant nanoparticle COVID-19 vaccine – Filing for World Health Organization Emergency Use Listing expected in August 2021 Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for […]